SunGen Pharma, Athenex Pharma Partner for Bivalirudin Launch

An anticoagulant injection with 2018 US Market Sales at $81.8M according to IQVIA data

SunGen Pharma will launch Bivalirudin for Injection in the near future through a joint venture with Athenex Pharmaceuticals. This tentatively approved U.S. ANDA is exclusively licensed from the current ANDA holder, Hainan Shuangcheng Pharmaceuticals.    U.S. Market Sales of Bivalirudin for Injection were $81.8 million for the year ending December 2018, according to IQVIA data. Bivalirudin is an anticoagulant (thrombin inhibitor) that helps prevent the formation of blood clots. Dr. Isaac Li...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters